Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jun 17, 2010


Myriad Genetics said last week that it has elected Heiner Dreismann to its board of directors, increasing the company's board size to eight.

Dreismann, considered a pioneer in the early adoption of PCR, worked for Roche from 1985 to 2006, during which time he held several senior positions, including president and CEO of Roche Molecular Systems; head of global business development at Roche Diagnostics; and member of Roche's global diagnostic executive committee.

He currently serves on the board of several public and private health care companies. Dreismann holds an MS in biology and PhD in microbiology/molecular biology from the University of Münster.

Response Genetics said last week that it has named Michael McNulty as chief operating officer.

McNulty most recently served as general manager of diagnostics at Agilent Technologies. He also held the position of vice president of laboratory operations at Berkeley HeartLab, now part of Celera Diagnostics. He has also held positions at Thaumdx and Quest Diagnostics predecessor SmithKline Beecham Healthcare Services. McNulty received a BS in microbiology and biochemistry from San Jose State University.

Pall Corporation has appointed Michael Egholm as chief technology officer, the company said this week.

Egholm will direct technology research across the company's Industrial and Life Sciences lines of business. He most recently served as CTO and vice president of R&D at 454 Life Sciences within Roche Applied Science, where he spearheaded several large high-profile programs including the Neandertal sequencing project and the sequencing of James Watson's genome.

Egholm has also held senior R&D positions with Molecular Staging, where he led commercialization of genome amplification technology; and Applied Biosystems, where he managed market development.

Egholm has a PhD in organic chemistry from the University of Copenhagen, where he was the lead inventor of peptide nucleic acids technology, a synthetic form of DNA.